CTOs on the Move


 
We are a biotechnology company dedicated to developing next-generation antibody therapeutics to improve the lives of patients with severe and life-threatening diseases.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.abpro.com
  • 68 Cummings Park Dr
    Woburn, MA USA 01801
  • Phone: 800.396.5890

Executives

Name Title Contact Details

Funding

Abpro raised $17.9M on 01/27/2020

Similar Companies

Crescendo Bioscience

Crescendo Bioscience is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Metacrine

We are a clinical-stage biopharmaceutical company focused on discovering and developing best-in-class therapies for patients with liver and gastrointestinal, or GI, diseases. Since our founding in 2014, we have invested in building a foundation of chemistry and biology expertise to drive innovative drug discovery and development. We believe these internal capabilities allow us to gain insights into disease targets and mechanisms and more quickly and purposefully design therapies with characteristics that we view as key to safety and efficacy. With this systematic approach, we have designed novel, proprietary farnesoid X receptor (FXR) clinical product candidates arising from a unique chemical scaffold with the potential to be best-in-class for non-alcoholic steatohepatitis, or NASH, and first- in-class for Inflammatory Bowel Disease, or IBD. In addition to our FXR program, we have continued to invest in drug discovery on other therapeutic targets that have effects on inflammation and/or fibrosis for which we believe we could develop proprietary small molecule therapies.

Sigtem Technology Inc

Sigtem Technology Inc is a Harleysville, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tessera Therapeutics

Tessera Therapeutics is pioneering GENE WRITING technology, which consists of multiple technology platforms designed to offer scientists and clinicians the ability to write therapeutic messages into the human genome, thereby curing diseases at their source. The GENE WRITING platform allows the correction of single nucleotides, the deletion or insertion of short sequences of DNA, and the writing of entire genes into the genome, offering the potential for a new category of genetic medicines with broad applications both in vivo and ex vivo. Tessera Therapeutics was founded by Flagship Pioneering in 2018, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.

Linkage Inc

Linkage Inc is a Burlington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.